BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Philip C. Andrews, Richard L. Ferrero, Peter C. Junk, Ish Kumar, Quynh Luu, Kim Nguyen, James W. Taylor. Bismuth(iii) complexes derived from non-steroidal anti-inflammatory drugs and their activity against Helicobacter pyloriDalton Transactions 2010; 39(11): 2861 doi: 10.1039/c000164c
2
Neil S. Seligman, Wingkan Sbar, Vincenzo Berghella. Pouch function and gastrointestinal complications during pregnancy after ileal pouch-anal anastomosisThe Journal of Maternal-Fetal & Neonatal Medicine 2011; 24(3): 525 doi: 10.3109/14767058.2010.494745
3
Nuno Almeida, Maria Manuel Donato, José Manuel Romãozinho, Cristina Luxo, Olga Cardoso, Maria Augusta Cipriano, Carol Marinho, Alexandra Fernandes, Carlos Calhau, Carlos Sofia. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?BMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0245-y
4
Alicia C. Marin, Olga P. Nyssen, Adrian G. McNicholl, Javier P. Gisbert. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-AnalysisDrugs 2017; 77(7): 765 doi: 10.1007/s40265-017-0730-4
5
Morris O. Makobongo, Leo Einck, Richard M. Peek, D. Scott Merrell, Asad U Khan. In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against Helicobacter pyloriPLoS ONE 2013; 8(7): e68917 doi: 10.1371/journal.pone.0068917
6
Javier P. Gisbert, Xavier Calvet, Juan Ferrándiz, Juan Mascort, Pablo Alonso-Coello, Mercè Marzo. Guía de práctica clínica sobre el manejo del paciente con dispepsia. Actualización 2012Atención Primaria 2012; 44(12): 727.e1 doi: 10.1016/j.aprim.2012.05.003
7
Helicobacter pylori Oncogenicity: Mechanism, Prevention, and Risk FactorsThe Scientific World Journal 2020; 2020: 1 doi: 10.1155/2020/3018326
8
A. Cuadrado-Lavin, J. R. Salcines-Caviedes, M. F. Carrascosa, P. Mellado, I. Monteagudo, J. Llorca, M. Cobo, M. R. Campos, B. Ayestaran, A. Fernandez-Pousa, E. Gonzalez-Colominas. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in SpainJournal of Antimicrobial Chemotherapy 2012; 67(1): 170 doi: 10.1093/jac/dkr410
9
Javier P. Gisbert, Adrian G. McNicholl. Optimization strategies aimed to increase the efficacy ofH. pylorieradication therapiesHelicobacter 2017; 22(4): e12392 doi: 10.1111/hel.12392
10
Javier P. Gisbert. Review: Second-line rescue therapy ofHelicobacter pyloriinfectionTherapeutic Advances in Gastroenterology 2009; 2(6): 331 doi: 10.1177/1756283X09347109
11
Yuqin Li, Xiayue Huang, Linhua Yao, Ruihua Shi, Guoxin Zhang. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysisWiener klinische Wochenschrift 2010; 122(13-14): 413 doi: 10.1007/s00508-010-1404-3
12
Philip C. Andrews, Richard L. Ferrero, Peter C. Junk, Roshani M. Peiris. A sweeter way to combat Helicobacter pylori? Bismuth(III) complexes and oxido-clusters derived from non-nutritive sweeteners and their activity against H. pyloriJournal of Organometallic Chemistry 2013; 724: 88 doi: 10.1016/j.jorganchem.2012.10.024
13
J. P. Gisbert. Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics 2012; 35(12): 1484 doi: 10.1111/j.1365-2036.2012.05117.x
14
Javier P. Gisbert, Jesús Barrio, Inés Modolell, Javier Molina-Infante, Angeles Perez Aisa, Manuel Castro-Fernández, Luis Rodrigo, Angel Cosme, Jose Luis Gisbert, Miguel Fernández-Bermejo, Santiago Marcos, Alicia C. Marín, Adrián G. McNicholl. Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin AllergyDigestive Diseases and Sciences 2015; 60(2): 458 doi: 10.1007/s10620-014-3365-2
15
Wen Gao, Hong Cheng, Fulian Hu, Jiang Li, Lihui Wang, Guibin Yang, Le Xu, Xiaoli Zheng. The Evolution of Helicobacter pylori Antibiotics Resistance Over 10 Years in Beijing, ChinaHelicobacter 2010; 15(5): 460 doi: 10.1111/j.1523-5378.2010.00788.x
16
Te-Fu Lin, Ping-I Hsu. Second-line rescue treatment of <i>Helicobacter pylori</i> infection: Where are we now?World Journal of Gastroenterology 2018; 24(40): 4548-4553 doi: 10.3748/wjg.v24.i40.4548
17
Zhi Qiang Song, Li Ya Zhou. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens forHelicobacter pylorieradicationJournal of Digestive Diseases 2016; 17(4): 260 doi: 10.1111/1751-2980.12334
18
Carmen Cofré. Helicobacter pylori: una puesta al día en pediatríaMedwave 2011; 11(07) doi: 10.5867/medwave.2011.07.5056
19
Wei-Chen Tai, Chien-Hua Chiu, Chih-Ming Liang, Kuo-Chin Chang, Chung-Mou Kuo, Yi-Chun Chiu, Keng-Liang Wu, Ming-Luen Hu, Yeh-Pin Chou, Shue-Shian Chiou, King-Wah Chiu, Chung-Huang Kuo, Tsung-Hui Hu, Ming-Tsung Lin, Seng-Kee Chuah. Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in TaiwanGastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/932478
20
Deng-Chyang Wu, Ping-I Hsu, Hui-Hwa Tseng, Feng-Woei Tsay, Kwok-Hung Lai, Chao-Hung Kuo, Sheng-Wen Wang, Angela Chen. Helicobacter pylori InfectionMedicine 2011; 90(3): 180 doi: 10.1097/MD.0b013e31821c9d1c
21
Erik C. von Rosenvinge, Graeme A. O'May, Sandra Macfarlane, George T. Macfarlane, Mark E. Shirtliff. Microbial biofilms and gastrointestinal diseasesPathogens and Disease 2013; 67(1): 25 doi: 10.1111/2049-632X.12020
22
Jun-Won Chung, Jeong Hoon Lee, Hwoon-Yong Jung, Sung-Cheol Yun, Tae-Hoon Oh, Kee Don Choi, Ho June Song, Gin Hyug Lee, Jin-Ho Kim. Second-line Helicobacter pylori Eradication: A Randomized Comparison of 1-week or 2-week Bismuth-containing Quadruple TherapyHelicobacter 2011; 16(4): 289 doi: 10.1111/j.1523-5378.2011.00844.x
23
F. Sierra, J. D. Forero, M. Rey, M. L. Botero, A. Cárdenas. Pilot study: miscellaneous therapy is highly successful forHelicobacter pylorieradicationAlimentary Pharmacology & Therapeutics 2013; 37(12): 1165 doi: 10.1111/apt.12329
24
Krisztina Hagymási, Zsolt Tulassay. Peptic ulcer: facts and questions – 2010Orvosi Hetilap 2010; 151(26): 1054 doi: 10.1556/oh.2010.28892
25
Hyuk Yoon, Nayoung Kim, Byoung Hwan Lee, Tae Jun Hwang, Dong Ho Lee, Young Soo Park, Ryoung Hee Nam, Hyun Chae Jung, In Sung Song. Moxifloxacin-Containing Triple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication RateHelicobacter 2009; 14(5): 429 doi: 10.1111/j.1523-5378.2009.00709.x
26
P Malfertheiner, F Megraud, C A O'Morain, J P Gisbert, E J Kuipers, A T Axon, F Bazzoli, A Gasbarrini, J Atherton, D Y Graham, R Hunt, P Moayyedi, T Rokkas, M Rugge, M Selgrad, S Suerbaum, K Sugano, E M El-Omar. Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus ReportGut 2017; 66(1): 6 doi: 10.1136/gutjnl-2016-312288
27
Tzung-Shiun Wu, Huang-Ming Hu, Fu-Chen Kuo, Chao-Hung Kuo. Eradication of Helicobacter pylori infectionThe Kaohsiung Journal of Medical Sciences 2014; 30(4): 167 doi: 10.1016/j.kjms.2013.11.003
28
Javier P. Gisbert, Ángeles Pérez-Aisa, Fernando Bermejo, Manuel Castro-Fernández, Pedro Almela, Jesús Barrio, Ángel Cosme, Inés Modolell, Felipe Bory, Miguel Fernández-Bermejo, Luis Rodrigo, Jesús Ortuño, Pilar Sánchez-Pobre, Sam Khorrami, Alejandro Franco, Albert Tomas, Iván Guerra, Eloisa Lamas, Julio Ponce, Xavier Calvet. Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori InfectionJournal of Clinical Gastroenterology 2013; 47(2): 130 doi: 10.1097/MCG.0b013e318254ebdd
29
Soichiro Sue, Nobumi Suzuki, Wataru Shibata, Tomohiko Sasaki, Hiroaki Yamada, Hiroaki Kaneko, Toshihide Tamura, Tomohiro Ishii, Masaaki Kondo, Shin Maeda. First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to PenicillinGastroenterology Research and Practice 2017; 2017: 1 doi: 10.1155/2017/2019802
30
Amin Talebi Bezmin Abadi. Therapy ofHelicobacter pylori: Present Medley and Future ProspectiveBioMed Research International 2014; 2014: 1 doi: 10.1155/2014/124607
31
Hidekazu Suzuki, Hideki Mori. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treatJournal of Gastroenterology 2018; 53(3): 354 doi: 10.1007/s00535-017-1407-1
32
Xiaojun He, Xiangwen Liao, Hongyan Li, Wei Xia, Hongzhe Sun. Bismuth-Induced Inactivation of Ferric Uptake Regulator fromHelicobacter pyloriInorganic Chemistry 2017; 56(24): 15041 doi: 10.1021/acs.inorgchem.7b02380
33
Olga P. Nyssen, Ángeles Pérez‐Aisa, Bojan Tepes, Luis Rodrigo‐Sáez, Pilar M. Romero, Alfredo Lucendo, Manuel Castro‐Fernández, Perminder Phull, Jesús Barrio, Luis Bujanda, Juan Ortuño, Miguel Areia, Natasa Brglez Jurecic, José María Huguet, Noelia Alcaide, Irina Voynovan, José María Botargues Bote, Inés Modolell, Jorge Pérez Lasala, Inés Ariño, Laimas Jonaitis, Manuel Dominguez‐Cajal, György Buzas, Frode Lerang, Monica Perona, Dmitry Bordin, Toni Axon, Antonio Gasbarrini, Ricardo Marcos Pinto, Yaron Niv, Limas Kupcinskas, Ante Tonkic, Marcis Leja, Theodore Rokkas, Lyudmila Boyanova, Oleg Shvets, Marino Venerito, Peter Bytzer, Adrian Goldis, Ilkay Simsek, Vincent Lamy, Krzysztof Przytulski, Lumír Kunovský, Lisette Capelle, Tomica Milosavljevic, María Caldas, Ana Garre, Francis Mégraud, Colm O'Morain, Javier P. Gisbert, Jennifer Hinojosa, Nuria Fernández, Javier Molina Infante, Horacio Alonso Galán, Tommaso Di Maira, Susana Isabel Alves, Sandra Saraiva, Luis Elvas, Daniel Brito, Ana Teresa Cadime, Polona Lampic, Aleksander Gruncic, Vid Leban, Luis Ferrer, Luis Fernandez Salazar, Angel Lanas, Vendel Kristensen, Stephan Brackmann, Jean Charles Delchier, Charo Anton, Blas Jose Gomez Rodriguez, Rinaldo Pellicano, Doron Boltin. Helicobacter pylori first‐line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp‐EuReg) Helicobacter 2020; 25(3) doi: 10.1111/hel.12686
34
Javier P. Gisbert, Marco Romano, Javier Molina-Infante, Alfredo J. Lucendo, Enrique Medina, Inés Modolell, Manuel Rodríguez-Tellez, Blas Gomez, Jesús Barrio, Monica Perona, Juan Ortuño, Inés Ariño, Juan Enrique Domínguez-Muñoz, Ángeles Perez-Aisa, Fernando Bermejo, Jose Luis Domínguez, Pedro Almela, Judith Gomez-Camarero, Judith Millastre, Elisa Martin-Noguerol, Antonietta G. Gravina, Marco Martorano, Agnese Miranda, Alessandro Federico, Miguel Fernandez-Bermejo, Teresa Angueira, Luis Ferrer-Barcelo, Nuria Fernández, Alicia C. Marín, Adrián G. McNicholl. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatmentsDigestive and Liver Disease 2015; 47(2): 108 doi: 10.1016/j.dld.2014.10.009
35
Eskandar Hajiani, Pezhman Alavinejad, Nahid Avandi, Abdol Rahim Masjedizadeh, Ali Akbar Shayesteh. Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical TrialMiddle East Journal of Digestive Diseases 2018; 10(4): 242 doi: 10.15171/mejdd.2018.117
36
J. P. Gisbert, M. Romano, A. G. Gravina, P. Solís-Muñoz, F. Bermejo, J. Molina-Infante, M. Castro-Fernández, J. Ortuño, A. J. Lucendo, M. Herranz, I. Modolell, F. del Castillo, J. Gómez, J. Barrio, B. Velayos, B. Gómez, J. L. Domínguez, A. Miranda, M. Martorano, A. Algaba, M. Pabón, T. Angueira, L. Fernández-Salazar, A. Federico, A. C. Marín, A. G. McNicholl. Helicobacter pylorisecond-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatmentsAlimentary Pharmacology & Therapeutics 2015; 41(8): 768 doi: 10.1111/apt.13128
37
Brunella Posteraro, Patrizia Posteraro, Maurizio Sanguinetti. Molecular Medical Microbiology2015; : 1237 doi: 10.1016/B978-0-12-397169-2.00068-8
38
Antonio Francesco Ciccaglione, Mara Di Giulio, Silvia Di Lodovico, Emanuela Di Campli, Luigina Cellini, Leonardo Marzio. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo studyJournal of Antimicrobial Chemotherapy 2019; 74(4): 1069 doi: 10.1093/jac/dky510
39
Javier P. Gisbert. Tratamientos de rescate ante el fracaso erradicador de Helicobacter pyloriGastroenterología y Hepatología 2011; 34(2): 89 doi: 10.1016/j.gastrohep.2010.10.013
40
Davide Roccarina, Francesco Franceschi, Maria Assunta Zocco, Matteo Garcovich, Giovanni Gasbarrini, Antonio Gasbarrini. Different Antibiotic No Culture Eradicating (DANCE) strategy: An easy way to manage H. pylori eradicationDigestive and Liver Disease 2012; 44(11): 889 doi: 10.1016/j.dld.2012.05.010
41
Bilal Ergül, Zeynal Doğan, Murat Sarikaya, Levent Filik. The Efficacy of Two-Week Quadruple First-Line Therapy with Bismuth, Lansoprazole, Amoxicillin, Clarithromycin onHelicobacter pyloriEradication: A Prospective StudyHelicobacter 2013; 18(6): 454 doi: 10.1111/hel.12086
42
Zhiqiang Song, Baojun Suo, Lingyun Zhang, Liya Zhou. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens forHelicobacter pyloriEradicationHelicobacter 2016; 21(6): 462 doi: 10.1111/hel.12313
43
Amin Talebi Bezmin Abadi. A Rare Case of Helicobacter pylori Mix Infections and Recurrence of Duodenal UlcersMOJ Clinical & Medical Case Reports 2014; 1(1) doi: 10.15406/mojcr.2014.01.00001
44
Yongming Liu, Chen Shen, Xihui Zhang, Huan Yu, Fujun Wang, Yangyun Wang, Leshuai W Zhang. Exposure and nephrotoxicity concern of bismuth with the occurrence of autophagyToxicology and Industrial Health 2018; 34(3): 188 doi: 10.1177/0748233717746810
45
Antonio Francesco Ciccaglione, Luigina Cellini, Laurino Grossi, Lamberto Manzoli, Leonardo Marzio. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment ofHelicobacter pyloriInfection: A Pilot StudyHelicobacter 2015; 20(5): 390 doi: 10.1111/hel.12209
46
Hazel Mitchell, Peter Katelaris. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infectionMedical Journal of Australia 2016; 204(10): 376 doi: 10.5694/mja16.00104
47
Stefan Hagel, Tony Bruns, Marcus Kantowski, Peter Fix, Thomas Seidel, Andreas Stallmach. Cholestatic hepatitis, acute acalculous cholecystitis, and hemolytic anemia: primary Epstein–Barr virus infection under azathioprineInflammatory Bowel Diseases 2009; 15(11): 1613 doi: 10.1002/ibd.20856
48
Marco Berning, Susanne Krasz, Joachim Labenz, Stephan Miehlke. Moderne Helicobacter-pylori-Therapien in Zeiten zunehmender AntibiotikaresistenzMedizinische Klinik 2010; 105(11): 787 doi: 10.1007/s00063-010-1135-2
49
Diego Burgos‐Santamaría, Adrian G. McNicholl, Javier P. Gisbert. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients GastroHep 2019; 1(6): 311 doi: 10.1002/ygh2.372
50
Jay Luther, William D. Chey, Richard J. Saad. A Clinician's Guide to Salvage Therapy for PersistentHelicobacter pyloriInfectionHospital Practice 2011; 39(1): 133 doi: 10.3810/hp.2011.02.383
51
J.-M. Liou, C.-C. Chen, C.-Y. Chang, M.-J. Chen, Y.-J. Fang, J.-Y. Lee, C.-C. Chen, S.-J. Hsu, Y.-C. Hsu, C.-H. Tseng, P.-H. Tseng, L. Chang, W.-H. Chang, H.-P. Wang, C.-T. Shun, J.-Y. Wu, Y.-C. Lee, J.-T. Lin, M.-S. Wu. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trialJournal of Antimicrobial Chemotherapy 2013; 68(2): 450 doi: 10.1093/jac/dks407
52
Jyh-Ming Liou, Po-Yueh Chen, Jiing-Chyuan Luo, Ji-Yuh Lee, Chieh-Chang Chen, Yu-Jen Fang, Tsung-Hua Yang, Chi-Yang Chang, Ming-Jong Bair, Mei-Jyh Chen, Yao-Chun Hsu, Wen-Feng Hsu, Chun-Chao Chang, Jaw-Town Lin, Chia-Tung Shun, Emad M. El-Omar, Ming-Shiang Wu, Jyh-Ming Liou, Yi-Chia Lee, Jaw-Town Lin, Chun-Ying Wu, Jeng-Yih Wu, Ching-Chow Chen, Chun-Hung Lin, Yu-Ren Fang, Ming-Jong Bair, Jiing-Chyuan Luo, Ming-Shiang Wu, Tsu-Yao Cheng, Ping-Huei Tseng, Han-Mo Chiu, Chun-Chao Chang, Chien-Chun Yu, Min-Chin Chiu, Yen-Nien Chen, Wen-Hao Hu, Chu-Kuang Chou, Chi-Ming Tai, Ching-Tai Lee, Wen-Lun Wang, Wen-Shiung Chang. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori InfectionGastroenterology 2018; 155(4): 1109 doi: 10.1053/j.gastro.2018.06.047
53
Jonathan Efron. Post-Surgical Recurrence of Ileal Crohn’s DiseaseWorld Journal of Surgery 2010; 34(7): 1627 doi: 10.1007/s00268-010-0498-0
54
Sarah Gurney, Laura Carvalho, Carrie Gonzalez, Esperanza Galaviz, Frances Sonstein. An Efficacious and Cost-Effective Pharmacologic Treatment for Helicobacter pyloriThe Journal for Nurse Practitioners 2014; 10(1): 22 doi: 10.1016/j.nurpra.2013.09.013
55
Jaime Natan Eisig, Fernando Marcuz Silva, Ricardo Correa Barbuti, Tomás Navarro-Rodriguez, Joaquim Prado P Moraes-Filho, José Pedrazzoli Jr. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good optionArquivos de Gastroenterologia 2011; 48(4): 261 doi: 10.1590/S0004-28032011000400008
56
Javier P. Gisbert. Rescue Therapy forHelicobacter pyloriInfection 2012Gastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/974594
57
Li-Yang Gu, Wei-Wei Lin, Hong Lu, Xiao-Yu Chen, Zhi-Zheng Ge, Xiao-Bo Li. Quadruple Therapy with Medications Containing Either Rufloxacin or Furazolidone as a Rescue regimen in the Treatment of Helicobacter pylori-Infected Dyspepsia Patients: A Randomized Pilot StudyHelicobacter 2011; 16(4): 284 doi: 10.1111/j.1523-5378.2011.00848.x
58
Javier P. Gisbert, Xavier Calvet, Juan Ferrándiz, Juan Mascort, Pablo Alonso-Coello, Mercè Marzo. Guía de práctica clínica sobre el manejo del paciente con dispepsia. Actualización 2012Gastroenterología y Hepatología 2012; 35(10): 725.e1 doi: 10.1016/j.gastrohep.2012.05.002
59
Zhiqiang Song, Liya Zhou, Jianzhong Zhang, Lihua He, Peng Bai, Yan Xue. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapyDigestive and Liver Disease 2016; 48(5): 506 doi: 10.1016/j.dld.2016.01.002
60
Myung Ho Jeong, Jun-Won Chung, Sang Jin Lee, Minsu Ha, Seok Hoo Jeong, Sunyoung Na, Byung Soo Na, Sung Keun Park, Yoon Jae Kim, Kwang An Kwon, Kwang Il Ko, Yunjeong Jo, Ki Baik Hahm, Hwoon-Yong Jung. Comparison of Rifabutin- and Levofloxacin-based Third-line Rescue Therapies forHelicobacter pyloriThe Korean Journal of Gastroenterology 2012; 59(6): 401 doi: 10.4166/kjg.2012.59.6.401
61
Meng‐Shu Hsieh, Chung‐Jung Liu, Wen‐Hung Hsu, Chia‐Jung Li, Pei‐Yun Tsai, Huang‐Ming Hu, Hsiang‐Yao Shih, Chien‐Yu Lu, Fang‐Jung Yu, Fu‐Chen Kuo, Deng‐Chyang Wu, Chao‐Hung Kuo. Gastric juice‐based PCR assay: An alternative testing method to aid in the management of previously treated Helicobacter pylori infection Helicobacter 2019; 24(2): e12568 doi: 10.1111/hel.12568
62
Amita Pathak, Victoria L. Blair, Richard L. Ferrero, Michael Mehring, Philip C. Andrews. Bismuth(iii) benzohydroxamates: powerful anti-bacterial activity against Helicobacter pylori and hydrolysis to a unique Bi34 oxido-cluster [Bi34O22(BHA)22(H-BHA)14(DMSO)6]Chem. Commun. 2014; 50(96): 15232 doi: 10.1039/C4CC07329K
63
Tural Safarov, Bukre Kiran, Melahat Bagirova, Adil M Allahverdiyev, Emrah Sefik Abamor. An overview of nanotechnology-based treatment approaches against Helicobacter PyloriExpert Review of Anti-infective Therapy 2019; 17(10): 829 doi: 10.1080/14787210.2019.1677464
64
Jyh-Ming Liou, Po-Yueh Chen, Yu-Ting Kuo, Ming-Shiang Wu. Toward population specific and personalized treatment of Helicobacter pylori infectionJournal of Biomedical Science 2018; 25(1) doi: 10.1186/s12929-018-0471-z
65
Temporin-SHa and Its Analogs as Potential Candidates for the Treatment of Helicobacter pyloriBiomolecules 2019; 9(10): 598 doi: 10.3390/biom9100598
66
G. Cammarota, M. Sanguinetti, A. Gallo, B. Posteraro. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infectionAlimentary Pharmacology & Therapeutics 2012; 36(3): 222 doi: 10.1111/j.1365-2036.2012.05165.x
67
Hyung Min Noh, Su Jin Hong, Jae Pil Han, Kyung Woo Park, Yun Nah Lee, Tae Hee Lee, Bong Min Ko, Joon Seong Lee, Moon Sung Lee. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin afterHelicobacter pyloriTreatment Failure in Clinical PracticeThe Korean Journal of Gastroenterology 2016; 68(5): 260 doi: 10.4166/kjg.2016.68.5.260
68
Jun-Won Chung, Gin Hyug Lee, Jin-Yong Jeong, Sun Mi Lee, Ji Hoon Jung, Kee Don Choi, Ho June Song, Hwoon-Yong Jung, Jin-Ho Kim. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistanceJournal of Gastroenterology and Hepatology 2012; 27(3): 493 doi: 10.1111/j.1440-1746.2011.06874.x
69
Alicia C Marin, Adrian G McNicholl, Javier P Gisbert. A review of rescue regimens after clarithromycin-containing triple therapy failure (forHelicobacter pylorieradication)Expert Opinion on Pharmacotherapy 2013; 14(7): 843 doi: 10.1517/14656566.2013.782286
70
A. Cuadrado-Lavin, J. R. Salcines-Caviedes, M. F. Carrascosa, T. Dierssen-Sotos, M. Cobo, M. R. Campos, B. Ayestaran, A. Fernandez-Pousa, E. Gonzalez-Colominas, S. Aresti-Zarate, M. Hernandez, E. L. Pascual. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trialJournal of Antimicrobial Chemotherapy 2012; 67(9): 2254 doi: 10.1093/jac/dks209
71
Sotirios D Georgopoulos, Vasilios Papastergiou, Stylianos Karatapanis. Current options for the treatment ofHelicobacter pyloriExpert Opinion on Pharmacotherapy 2013; 14(2): 211 doi: 10.1517/14656566.2013.763926
72
Jyh-Ming Liou, Ming-Shiang Wu, Jaw-Town Lin. Treatment ofHelicobacter pyloriinfection: Where are we now?Journal of Gastroenterology and Hepatology 2016; 31(12): 1918 doi: 10.1111/jgh.13418